ASH 2018 | Monoallelic TP53-mutated CLL patients show durable response to ibrutinib monotherapy

VJHemOnc is committed to improving our service to you

Carsten Niemann

Carsten Niemann, MD, PhD, of Copenhagen University Hospital, Copenhagen, Denmark, describes how a recent study found chronic lymphocytic leukemia (CLL) patients responded better to ibrutinib monotherapy if they only had a monoallelic TP53 aberration, compared to those with biallelic. Monoallelic TP53-mutated patients had better progression-free survival compared to biallelic patients. This knowledge has the potential to identify patients who would benefit from single-agent ibrutinib therapy and those who would not. This interview was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter